Risk of de novo HCC in patients with MASLD following direct-acting antiviral-induced cure of HCV infection
Chen‐Hua Liu(National Taiwan University Hospital), Jia‐Horng Kao(National Taiwan University Hospital), Chih‐Lin Lin(Chung Shan Medical University Hospital), Pei‐Jer Chen(National Taiwan University), Chi-Yi Chen(Chia-Yi Christian Hospital), Sheng‐Shun Yang(Taichung Veterans General Hospital), Cheng‐Yuan Peng(China Medical University), Chun‐Jen Liu(National Taiwan University), Pin‐Nan Cheng(National Cheng Kung University Hospital), Shang‐Chin Huang(National Taiwan University Hospital), Tai‐Chung Tseng(National Taiwan University Hospital), Yu‐Ping Chang(National Taiwan University Hospital), Yu‐Lueng Shih(Tri-Service General Hospital), Tung‐Hung Su(National Taiwan University), Yu‐Jen Fang(National Taiwan University), Wei‐Yu Kao(Taipei Medical University Hospital)
Cited by 33
Related Papers
Mitotic and G <sub>2</sub> Checkpoint Control: Regulation of 14-3-3 Protein Binding by Phosphorylation of Cdc25C on Serine-216
|Science|1997|1.3k
Global patterns of hepatocellular carcinoma management from diagnosis to death: the <scp>BRIDGE</scp> Study
|Liver International|2015|1.3k
SIRveNIB: Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma
|Journal of Clinical Oncology|2018|653
Hepatitis B Virus Genotype and DNA Level and Hepatocellular Carcinoma: A Prospective Study in Men
|JNCI Journal of the National Cancer Institute|2005|569